Prognostic and predictive factors in pancreatic cancer.
Prognostic and predictive factors in pancreatic cancer.
复制标题
DOI：
10.18632/oncotarget.27518
复制
发表时间：
2020-03-10
期刊：
影响因子：
--
通讯作者：
Santini, Daniele
中科院分区：
文献类型：
--
作者：
Dell'Aquila, Emanuela;Fulgenzi, Claudia Angela Maria;Santini, Daniele
胰腺癌是全球癌症死亡的主要原因之一。它的高死亡率多年来一直没有改变。放射治疗和手术被认为是早期和局部晚期的标准治疗方法。化疗是转移性患者的唯一选择。两种治疗方案，i. e. 5-氟尿嘧啶-伊立替康-奥沙利铂（FOLFIRINOX）的联合和nab-紫杉醇与吉西他滨的联合已经显示出改善转移性胰腺癌患者的结果。然而，没有标准化的预测生物标志物能够识别从治疗中获益最多的患者。CA 19 -9是研究最多的预后生物标志物，其预测作用尚不清楚。其他临床、组织学和分子生物标志物也出现在预后和预测环境中。本综述的目的是提供临床实践中使用的预后和预测标志物的概述，并探讨胰腺癌治疗选择和定制治疗方面最有前途的研究领域。
Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil- irinotecan-oxaliplatin (FOLFIRINOX) and the association of nab-paclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.